Hansa Biopharma receives positive CHMP opinion for Idefirix[TM] (imlifidase) for kidney transplant in EU
The positive opinion marks an important milestone as the Company prepares its transformation into a commercial stage biopharmaceutical company.Lund, Sweden June 25, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending conditional approval of Idefirix[TM] (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch